BrightSpring Health Services, Inc. Q4 FY2023 earnings call

Jon Rousseau thanked employees and discussed the company's mission of making a difference in people's lives. He outlined the care model with three pillars: pharmacy, provider, and home-based primary care. Jim Mattingly discussed 2023 results, including revenue growth and adjusted EBITDA, and segment performance details. The company emphasized organic growth, integrated care, and accretive acquisitions. They also highlighted investments in people, systems, and processes.

For the fourth quarter of 2023, pharmacy revenue year-over-year increased 406 million, or 29.5%, to $1.8 billion, with pharmacy segment EBITDA decreasing 4 million, or 3.9%, to $93 million. Provider revenue increased 25 million, or 4.4%, to $589 million, and provider segment EBITDA increased 9 million, or 12%, to $86 million. For the full year 2023, pharmacy revenue increased 1.3 billion, or 23.9%, to $6.5 billion, with pharmacy segment EBITDA increasing 27 million or 7.7% to $371 million. Provider revenue increased 122 million or 5.6% to $2.3 billion and provider segment EBITDA increased 18 million or 6.2% to $307 million.

For 2024, revenue is projected between $9.35 billion and $9.50 billion, with pharmacy revenue $6.95-$7.05 billion and provider revenue $2.40-$2.45 billion. Adjusted EBITDA is expected to be $550 million to $564 million. The company mentioned debt paydown, credit upgrades, and focus on deleveraging towards a below 3x leverage target.

Q: Jamie Perse asked about the misunderstood complementary nature of businesses and sales synergies, and long-term margin targets.

A: Jon Rousseau explained about the need for multiple services for complex patients, internal care integrations contributing to EBITDA, and future opportunities in value-based care. He also discussed margin targets and efficiency initiatives.

Q: Brian Tanquilut inquired about growth rates, acquisitions, and guidance details.

A: Jon Rousseau talked about historical growth rates, excitement about growth levers, and expected M&A activity. Jim Mattingly clarified guidance and quality incentive payments.

Q: AJ Rice asked about quality incentive payments, acquisitions pipeline.

A: Jon Rousseau discussed the tiering structure of incentives, conservative assumptions, and a robust acquisitions pipeline with potential deals and low multiples.

Q: Joanna Gajuk asked about organic revenue growth, guidance, and operating cash flow.

A: Jennifer Phipps and Jim Mattingly provided details on organic growth, guidance components, and operating cash flow expectations.

Q: Whit Mayo asked about acquisition of I-SNPs and strategic thoughts.

A: Jon Rousseau explained the small deal, value-based care strategy, and expansion plans.

Q: Stephen Baxter asked about pharmacy revenue growth assumptions and quality incentive payments.

A: Jon Rousseau discussed pharmacy growth assumptions, conservatism in guidance, and confirmation of quality incentive payment expectations.

Q: Ann Hynes asked about guidance range assumptions and leverage targets.

A: Jon Rousseau talked about range assumptions and long-term leverage targets below 3x.

Q: Jack Wallace asked about value-based care strategy and capital deployment.

A: Jon Rousseau explained organic growth in primary care, infrastructure investments, and EBITDA expectations for value-based care.

Q: Pito Chickering asked about pharmacy growth and margin interplay.

A: Jon Rousseau discussed pharmacy drug distribution expectations and margin interplay between segments and SG&A leverage.